Mylan, Biocon Announce US Launch Of Trastuzumab Biosimilar Ogivri - Quick Facts

Pharmaceutical company Mylan N.V. (MYL) and India-based Biocon Ltd. announced Monday the U.S. launch of Ogivri (trastuzumab-dkst), a biosimilar to Herceptin (trastuzumab). The product is co-developed by Mylan and Biocon.

from RTT - Biotech https://ift.tt/34HeIlI
via IFTTT